the Edanz group (www.edanzediting.com) provided editorial assistance. First, DNA microarray analysis was performed on peripheral blood mononuclear cells (PBMCs) from Thai control, hyperlipidemia and CHD male patients (= 7). Gene expression profiling revealed eight up-regulated genes common between hyperlipidemia and CHD Rabbit polyclonal to ALS2CR3 patients, but not controls. We sought to verify and compare -defensin expression among the groups using: 1) real-time quantitative RT-PCR (qRT-PCR) to determine -defensin mRNA expression (= 10), and 2) enzyme-linked immunosorbent assay to determine BKM120 (NVP-BKM120, Buparlisib) plasma HNP 1C3 levels (= 17). Statistically significant differences and correlations between groups BKM120 (NVP-BKM120, Buparlisib) were determined by the MannCWhitney test or the KruskalCWallis test, and the Rho-Spearman correlation, respectively. Results We found that -defensin mRNA expression increased (mean 2-fold switch) in the hyperlipidemia (= 0.043) and CHD patients (= 0.05) compared with the controls. CHD development moderately correlated with -defensin mRNA expression (= 0.429, = 0.023) and with plasma HNP 1C3 levels (= 0.486, = 0.000). Conclusions Increased -defensin expression is usually a potential inflammatory marker that may predict the risk of CHD development in Thai hyperlipidemia patients. test, and those among three groups were determined by the KruskalCWallis test. Correlations between CHD development and -defensin mRNA expression or plasma HNP 1C3 levels were analyzed by the Rho-Spearman correlation analysis. The level was set at? ?0.05 at a 95?% confidence interval. All statistical analyses were performed using SPSS version 11.5 (SPSS, Chicago, IL, USA). Results Clinical manifestations The baseline characteristics of all patients and healthy controls are summarized in Table?1. The healthy and hyperlipidemia patients did not differ in age, whereas the CHD patients were significantly older compared with the control and hyperlipidemia groups (both valuesnormal controls, and patients with hyperlipidemia and coronary heart disease, respectively Data are shown as medians (ranges). The differences in each variable between two groups (N vs. H, H vs. CHD, and N vs. CHD) were decided using the MannCWhitney test. The level was set at? ?0.05 at a 95?% confidence interval. The significantly different variables between groups are shown by value in strong total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein Profiling of hyperlipidemia and CHD patients discloses common up-regulated genes We observed nine up-regulated genes (entity list 2) in the hyperlipidemia group and 40 genes (entity list 1) in the CHD group (Fig.?2) relative to the baseline by DNA microarray analysis. Of these, eight genes were common to both groups of patients (Fig.?1c and ?andd,d, and Table?2). Based on these results, we sought to validate -defensin (one of eight intersected genes) expression and its association with CHD development. Open in a separate windows Fig. 2 Gene expression profiling by DNA microarrays. a and b Heat maps of differentially expressed transcripts in peripheral blood mononuclear cells (PBMCs) from coronary heart disease (CHD) patients post coronary bypass grafting vs. control a BKM120 (NVP-BKM120, Buparlisib) and hyperlipidemia BKM120 (NVP-BKM120, Buparlisib) patients vs. control b. Total RNA was extracted from 2 million PBMCs (test for statistical significance of mRNA expression and HNP levels (=0.030) levels, but not TG (=0.030) or HDL (mouse model, which is important for studying the mechanisms by which LDL, as a sole mediator, induces atherosclerosis. Murine PMNs lack HNPs, which raises the question of the importance of HNPs in the atherosclerotic pathology observed in mice. The study has demonstrated that this HNP-mediated inflammatory responses and the direct effects of LDL around the pathogenesis of cardiovascular diseases are equally important. PMN infiltration in BKM120 (NVP-BKM120, Buparlisib) chronic arterial inflammation, and the pivotal role of PMN contributing to atherogenesis was supported by a decrease in the atherosclerotic burden when PMNs were depleted in mice [29]. Our cross-sectional findings demonstrated increased expression of -defensin during CHD development. Therefore, this.